Log in

NASDAQ:GHDX - Genomic Health Stock Price, Forecast & News

0.00 (0.00 %)
(As of 11/8/2019)
Today's Range
Now: $63.44
50-Day Range
MA: $65.33
52-Week Range
Now: $63.44
Average Volume1.05 million shs
Market Capitalization$2.38 billion
P/E Ratio60.42
Dividend YieldN/A
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:GHDX



Sales & Book Value

Annual Sales$394.11 million
Cash Flow$1.45 per share
Book Value$7.48 per share


Net Income$25.68 million


Market Cap$2.38 billion
Next Earnings Date2/18/2020 (Estimated)

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) announced its quarterly earnings data on Monday, November, 11th. The medical research company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.11. Genomic Health had a net margin of 12.81% and a return on equity of 19.62%. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Genomic Health.

What price target have analysts set for GHDX?

8 Wall Street analysts have issued 1 year price objectives for Genomic Health's shares. Their forecasts range from $55.00 to $72.00. On average, they anticipate Genomic Health's stock price to reach $68.67 in the next year. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Price Targets for Genomic Health.

What is the consensus analysts' recommendation for Genomic Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.

What are Wall Street analysts saying about Genomic Health stock?

Here are some recent quotes from research analysts about Genomic Health stock:
  • 1. According to Zacks Investment Research, "Over the past year, Genomic Health has been outperforming its industry. The company is registering robust top-line growth banking on solid performance in the United States and internationally. In the last-reported quarter, breast cancer revenues were strong driven by increased Oncotype DX Breast Recurrence Score test usage globally which is amplifying on favorable results from the landmark TAILORx trial. Within the prostate cancer space, the company is seeing robust improvement in volume as the Oncotype DX GPS test consistently leads the market in low- and intermediate-risk prostate cancer test adoption. However, the company’s sole reliance on the Breast Oncotype DX test is a concern. Moreover, the company continues to face fierce competition for Oncotype DX tests." (7/31/2019)
  • 2. Canaccord Genuity analysts commented, "We are also lowering our price target from $77 to the deal price of $72. Our prior $77 PT used a 6.7x multiple on our 2021 revenue estimate of $540M. We note that our peer group (as of today) is trading at 6.7x our 2020 revenue estimates." (7/30/2019)

Has Genomic Health been receiving favorable news coverage?

News stories about GHDX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Genomic Health earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Genomic Health.

Who are some of Genomic Health's key competitors?

What other stocks do shareholders of Genomic Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include NVIDIA (NVDA), Revance Therapeutics (RVNC), Horizon Therapeutics (HZNP), Illumina (ILMN), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), Baidu (BIDU), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH).

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)
  • Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 63)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 60)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56)

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.85%), Eagle Asset Management Inc. (1.22%), Carillon Tower Advisers Inc. (0.95%), Pictet Asset Management Ltd. (0.63%), Man Group plc (0.54%) and Russell Investments Group Ltd. (0.34%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which major investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, State Street Corp, Russell Investments Group Ltd., SG Americas Securities LLC, First Trust Advisors LP, AMI Asset Management Corp, Dupont Capital Management Corp and Voloridge Investment Management LLC. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kim Mceachron, Kimberly J Popovits, Laura Leber and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which major investors are buying Genomic Health stock?

GHDX stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Eagle Asset Management Inc., Barclays PLC, State of New Jersey Common Pension Fund D, Squarepoint Ops LLC, GABELLI & Co INVESTMENT ADVISERS INC., Rhumbline Advisers and Gabelli Funds LLC. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $63.44.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.38 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.View Additional Information About Genomic Health.

What is Genomic Health's official website?

The official website for Genomic Health is http://www.genomichealth.com/.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]

MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  377 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel